invasive aspergillosis: results of multicenter study
Article Quality & Performance Metrics
Readership in this journal
SteadyRanked #19 of 24 articles by views in basic and clinical neuroscience
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
Abstract
We present the results of a multicenter study of 445 patients with “proven” and “probable” invasive aspergillosis (EORTC/MSG, 2008). Invasive aspergillosis usually occurs in patients with hematological malignancies (88 %), main underlying diseases were acute myeloid and acute lymphoblastic leukemia. The risk factors: prolonged agranulocytosis (64 %), cytostatic chemotherapy (57 %), corticosteroid treatment (45 %), and allogeneic hematopoietic stem cells transplantation (29 %). The pathogens – A. fumigatus (42 %), A. niger (33 %), and A. flavus (21 %). The main site of infection were lungs (86 %). 12 week overall survival was 83 %. Bronchoscopy use for the early diagnosis (p = 0.01), adequate
therapy with voriconazole (p = 0.002) and secondary antifungal prophylaxis (p = 0.0003) were positive prognostic factors for survival of patients with invasive aspergillosis.
| Reference Key |
klimko2014onkogematologiinvasive
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;N. N. Klimko;O. V. Shadrivova;S. N. Khostelidi;E. A. Desyatik;Yu. V. Borzova;R. M. Chernopyatova;E. V. Shagdileeva;A. G. Volkova;M. O. Popova;I. S. Zyuzgin;O. S. Ruzhinskaya;O. Ye. Ryabykina;N. V. Medvedeva;A. S. Kolbin;E. G. Boychenko;T. S. Bogomolova;S. M. Ignatieva;L. S. Zubarovskaya;B. V. Afanasiev |
| Journal | basic and clinical neuroscience |
| Year | 2014 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.